Previous 10 |
Puma Biotechnology, Inc. (PBYI) Q3 2018 Earnings Call November 01, 2018 4:30 pm ET Executives Mariann Ohanesian - Puma Biotechnology, Inc. Alan H. Auerbach - Puma Biotechnology, Inc. Steven Lo - Puma Biotechnology, Inc. Charles R. Eyler - Puma Biotechnology, Inc. Analysts ...
The following slide deck was published by Puma Biotechnology, Inc. in conjunction with their 2018 Q3 earnings Read more ...
Puma Biotechnology (NYSE: PBYI ) Q3 results ($M): Revenues: 62.6 (+999%); Nerlynx sales: 52.6 (+762.3%). More news on: Puma Biotechnology, Inc., Healthcare stocks news, Earnings news and commentary, Stocks on the move, Read more ...
Puma Biotechnology (NYSE: PBYI ): Q3 Non-GAAP EPS of $0.17 beats by $1.14 ; GAAP EPS of -$0.37 beats by $0.60 . Revenue of $62.6M (+926.2% Y/Y) beats by $4.66M . Shares -35.6% . Press Release More news on: Puma Biotechnology, Inc., Earnings news and commentary, Healthcare stock...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced financial results for the third quarter ended September 30, 2018. Unless otherwise stated, all comparisons are for the third quarter 2018 compared to the third quarter 2017. Net product revenue in the third q...
News in focus: REPH, MNKD Recro Pharma plans to resubmit NDA Discussion : On September 4, Recro Pharma ( REPH ) reported positive outcome of its meeting with the FDA regarding its NDA for IV meloxicam that was rejected in last May. Based on the discussion with the FDA, the comp...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced that on September 5, 2018 the Compensation Committee of Puma’s Board of Directors approved the grant of inducement restricted stock unit awards covering an aggregate of 31,125 shares of Puma common stock t...
Neratinib becomes the first anti-HER2 treatment to be EC-approved as extended adjuvant therapy for early stage hormone receptor positive HER2-positive breast cancer following adjuvant trastuzumab-based therapy Treatment with neratinib in the approved European indication resulted in ...
Biotechs continue their modest rally. The SPDR S&P Biotech ETF ( XBI +1.9% ) is up albeit on below average. It has jumped 6% since last week. More news on: SPDR Biotech ETF, Ionis Pharmaceuticals, Inc., Alnylam Pharmaceuticals, Inc., Healthcare stocks news, Stocks on the ...
News, Short Squeeze, Breakout and More Instantly...
Puma Biotechnology Inc Company Name:
PBYI Stock Symbol:
NASDAQ Market:
Puma Biotechnology Inc Website:
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, will host a conference call at 1:30 p.m. PDT/4:30 p.m. EDT on Thursday, August 1, 2024, following the release of its second quarter 2024 financial results. The call may be accessed by dialing 1-877-709-8150 (domestic) or 1-...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of alisertib for the treatment of patients with advanced osimertinib-resistant epidermal growth factor receptor-mutated (EGFR-mutated) non-small cell lung cancer (NCT04085315) at the 2024 American Soc...
Puma Biotechnology, Inc. (NASDAQ: PBYI), a biopharmaceutical company, announced the presentation of biomarker findings from a Phase II randomized clinical trial of alisertib alone vs. alisertib + fulvestrant for the treatment of patients with endocrine and CDK4/6 inhibitor (CDK 4/6i) resistant, h...